ANDAORALFOR SUSPENSION
Approved
Aug 2007
Lifecycle
Post-LOE
Competitive Pressure
60/100
Mechanism of Action
[see Microbiology ()].
Indications (12)
acute otitis media due to Sequal to 40 kg with: • Recurrentpersistent acute otitis media due to Sdevelopment of drug-resistant bacteriamaintain the effectiveness of amoxicillinclavulanate potassium for oral suspensionother antibacterial drugsamoxicillinclavulanate potassium for oral suspension should be used only to treatprevent infectionsstrongly suspected to be caused by susceptible bacteriastrongly suspected to be caused by bacteria